ProKidney Corp. (NASDAQ:PROK) Receives Average Rating of “Hold” from Brokerages

ProKidney Corp. (NASDAQ:PROK) has been given a consensus recommendation of “Hold” by the seven brokerages that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $7.40.

Several equities research analysts have weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of ProKidney in a research note on Thursday, January 22nd. HC Wainwright started coverage on ProKidney in a research report on Tuesday, December 16th. They issued a “buy” rating and a $12.00 price objective for the company.

ProKidney Trading Down 6.4%

Shares of NASDAQ PROK opened at $1.90 on Friday. ProKidney has a 12-month low of $0.46 and a 12-month high of $7.13. The stock’s fifty day simple moving average is $2.26 and its two-hundred day simple moving average is $2.54. The stock has a market capitalization of $571.58 million, a PE ratio of -3.45 and a beta of 1.78.

ProKidney (NASDAQ:PROK) last posted its earnings results on Monday, November 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). The company had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $0.04 million. On average, equities analysts predict that ProKidney will post -0.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Brian Jg Pereira sold 502,136 shares of the business’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $2.37, for a total transaction of $1,190,062.32. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 41.49% of the company’s stock.

Institutional Trading of ProKidney

Large investors have recently bought and sold shares of the stock. Zullo Investment Group Inc. acquired a new position in ProKidney during the 3rd quarter valued at approximately $28,000. AQR Capital Management LLC grew its holdings in shares of ProKidney by 106.4% during the first quarter. AQR Capital Management LLC now owns 52,570 shares of the company’s stock valued at $46,000 after buying an additional 27,098 shares during the last quarter. FNY Investment Advisers LLC increased its position in shares of ProKidney by 590,620.0% in the 4th quarter. FNY Investment Advisers LLC now owns 59,052 shares of the company’s stock valued at $132,000 after acquiring an additional 59,062 shares during the period. Catalyst Funds Management Pty Ltd purchased a new position in ProKidney in the 2nd quarter worth $36,000. Finally, Jefferies Financial Group Inc. acquired a new stake in ProKidney during the 3rd quarter worth about $158,000. Hedge funds and other institutional investors own 51.59% of the company’s stock.

About ProKidney

ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.